Approval · Notice of Compliance 28897 · 2022
RYLAZE: Notice of Compliance 28897
Issued September 2, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28897
- Date
- September 2, 2022
- Company
- Jazz Pharmaceuticals Ireland LimitedDublin, Dublin, Ireland
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RYLAZE | 02530406 | Marketed |
Medicinal ingredients
- CRISANTASPASE, RECOMBINANT 10 MG per 0.5ML